Trial reportAntimicrobial agents and chemotherapy2006
Population pharmacokinetics of tigecycline in patients with complicated intra-abdominal or skin and skin structure infections.
Trial report in Antimicrobial agents and chemotherapy, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 67 citations in OpenAlex.
- Population Pharmacokinetics of Tigecycline and Implications for Individualized Therapy Optimization: A Systematic Review.Drug design, development and therapy · 2025Pooled it
- Population Pharmacokinetics of Tigecycline: A Systematic Review.Drug design, development and therapy · 2022Pooled it
- Population pharmacokinetic analysis for a single 1,200-milligram dose of oritavancin using data from two pivotal phase 3 clinical trials.Antimicrobial agents and chemotherapy · 2015Trial
- Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.Antimicrobial agents and chemotherapy · 2010Trial
- Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections.Antimicrobial agents and chemotherapy · 2008Trial
- Evaluation of tigecycline penetration into colon wall tissue and epithelial lining fluid using a population pharmacokinetic model and Monte Carlo simulation.Antimicrobial agents and chemotherapy · 2007Trial
- Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.Antimicrobial agents and chemotherapy · 2007Trial
- Application of Machine Learning Models to Predict Tigecycline Exposure in Critically Ill Patients Using Different Limited Sampling Strategies.Drug design, development and therapy · 2026Article
- Evaluation of the stability of tigecycline in elastomeric infusion devices used for outpatient parenteral antimicrobial therapy.JAC-antimicrobial resistance · 2025Article
- Prediction and analysis of toxic and side effects of tigecycline based on deep learning.Frontiers in microbiology · 2024Article
- Population pharmacokinetics and individualized dosing of tigecycline for critically ill patients: a prospective study with intensive sampling.Frontiers in pharmacology · 2024Article
- Population pharmacokinetics of tigecycline in critically ill patients.Frontiers in pharmacology · 2023Article
- Tissue Penetration of Antimicrobials in Intensive Care Unit Patients: A Systematic Review-Part II.Antibiotics (Basel, Switzerland) · 2022Review
- Tigecycline Dosing Strategies in Critically Ill Liver-Impaired Patients.Antibiotics (Basel, Switzerland) · 2022Article
- Optimal empiric treatment for KPC-2-producing Klebsiella pneumoniae infections in critically ill patients with normal or decreased renal function using Monte Carlo simulation.BMC infectious diseases · 2021Article
- Therapeutic Drug Monitoring of Tigecycline in 67 Infected Patients and a Population Pharmacokinetics/Microbiological Evaluation ofFrontiers in microbiology · 2021Article
- Effect of pharmacokinetic/pharmacodynamic ratio on tigecycline clinical response and toxicity in critically ill patients with multidrug-resistant Gram-negative infections.SAGE open medicine · 2020Article
- Colistin Combined With Tigecycline: A Promising Alternative Strategy to CombatFrontiers in microbiology · 2019Article
- Evaluation of treatment options for methicillin-resistantInfection and drug resistance · 2019Article
- Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study.Critical care (London, England) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tigecycline, a first-in-class expanded glycylcycline antimicrobial agent, has demonstrated efficacy in the treatment of complicated skin and skin structure infections (cSSSI) and complicated intra-abdominal (cIAI) infections. A population pharmacokinetic (PK) model for tigecycline was developed for patients with cSSSI or cIAI enrolled in two phase 2 clinical trials, and the influence of selected demographic factors and clinical laboratory measures was investigated. Tigecycline was administered as an intravenous loading dose followed by a 0.5- or 1-h infusion every 12 h for up to 14 days. Blood samples were collected the day before or the day of hospital discharge for the determination of serum tigecycline concentrations. Patient covariates were evaluated using stepwise forward (alpha = 0.05) and backward (alpha = 0.001) procedures. The predictive performance of the model was assessed separately using pooled data from either two phase 3 studies for patients with cSSSI or two phase 3 studies for patients with cIAI. A two-compartment model with zero-order input and first-order elimination adequately described the steady-state tigecycline concentration-time data. Tigecycline clearance was shown to increase with increasing weight, increasing creatinine clearance, and male gender (P < 0.001). The final model provided a relatively unbiased fit to each data set. Individual predicted values of the area under the concentration-time curve from 0 to 12 h (AUC(0-12)) were generally unbiased (median prediction error, -1.60% to -3.78%) and were similarly precise (median absolute prediction error, <4%) when compared across data sets. The population PK model provided the basis to obtain individual estimates of steady-state AUC(0-12) in later exposure-response analyses of tigecycline safety and efficacy in patients with cSSSI or cIAI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.